E 4021

Drug Profile

E 4021

Latest Information Update: 10 Nov 1997

Price : $50

At a glance

  • Originator Eisai Co Ltd
  • Developer Schering-Plough
  • Class Anti-ischaemics; Antiplatelets; Heart failure therapies
  • Mechanism of Action Type 5 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Angina pectoris; Heart failure; Pulmonary hypertension; Thrombosis

Most Recent Events

  • 10 Nov 1997 Discontinued-Preclinical for Thrombosis in USA (Unknown route)
  • 06 Jun 1997 Preclinical development for Thrombosis in USA (Unknown route)
  • 05 Jul 1996 Discontinued-II for Angina pectoris in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top